Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 17,818 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: dose level 3 Clear all

Conditions: Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma, EBV-Related Sarcoma
Interventions: Nanatinostat, Valganciclovir, Pembrolizumab; Drug
Lead sponsor: Viracta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Stanford, California • Aurora, Colorado • Houston, Texas

Conditions: Kidney Transplantation in Highly Sensitized Patients
Interventions: Imlifidase, PLEX, IVIg, Anti-CD20 antibodies, Eculizumab, Remain on wait list; Drug · Procedure · Other
Lead sponsor: Hansa Biopharma AB; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more

Conditions: Pancreatic Cancer
Interventions: PLDR; Radiation
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: AZD1613, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Glendale, California

Conditions: Renal Impairment
Interventions: AZD0780; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 5
States / cities: Lake Forest, California • Hialeah, Florida • Orlando, Florida + 1 more

Conditions: Menopause, Estrogen Deficiency, Aging, Adiposity
Interventions: Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Alzheimer's Disease
Interventions: CTS21166 (ZPQ-21166); Drug
Lead sponsor: CoMentis; Industry
Eligibility: 22 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome, Mycosis Fungoides
Interventions: Recombinant human Interleukin-15 (rhIL-15), Mogamulizumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neuroblastoma
Interventions: Related donor transplant, Cord blood transplant, Busulfan, Thymoglobulin, Fludarabine; Procedure · Drug
Lead sponsor: Columbia University; Other
Eligibility: Up to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia or Schizoaffective
Interventions: Lumateperone Capsule, Lumateperone LAI; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Los Alamitos, California • Atlanta, Georgia • Marlton, New Jersey

Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation; Drug · Other · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 50 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 3
States / cities: Salt Lake City, Utah • Seattle, Washington

Conditions: Neoplasm
Interventions: SGT-53; Genetic
Lead sponsor: SynerGene Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: ADHD, Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine and OROS Methylphenidate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Epilepsy
Interventions: Diazepam Buccal Film, Diastat® Rectal Gel (Valeant Pharmaceuticals USA); Drug
Lead sponsor: Aquestive Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Winter Park, Florida

Conditions: Healthy Volunteer
Interventions: ABBV-142, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8
Interventions: Pyrvinium Pamoate; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cervical Cancer, Precancerous Condition
Interventions: imiquimod, Ablative or excisional therapy; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 8
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more

Conditions: Advanced Solid Tumor
Interventions: PM14; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: 7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions: Bevacizumab, Sorafenib Tosylate, Pharmacological Study, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 5
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 66
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more

Conditions: Advanced Solid Tumors
Interventions: 3 mg/kg Q3W MSB2311 Injection, 10 mg/kg Q3W MSB2311 Injection, 20 mg/kg Q3W MSB2311 Injection, 10 mg/kg Q2W MSB2311 Injection; Drug
Lead sponsor: Transcenta Therapeutics (Hangzhou) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Irritation/Irritant
Interventions: 350 mg Donepezil Transdermal Patch, Placebo Patch; Drug
Lead sponsor: Teikoku Pharma USA, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 7
States / cities: Phoenix, Arizona • Fresno, California • Garden Grove, California + 4 more

Conditions: Solid Tumors
Interventions: EMD 1204831; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer

A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.

A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

Cardiometabolic Consequences of the Loss of Ovarian Function

Safety Study of CTS21166 to Treat Alzheimer Disease

Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Safety Study of Infusion of SGT-53 to Treat Solid Tumors

Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer

Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia

PM14 Administered Intravenously to Patients With Advanced Solid Tumors

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily

A Phase I Study of MSB2311 in Advanced Solid Tumors

Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System

First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors